Abstract:The malignant transformation of normal cells is driven by both genetic and epigenetic changes. With the advent of next-generation sequencing and large-scale international consortia, it is now possible to profile the genomes and epigenomes of thousands of primary tumors from nearly every cancer type. These studies clearly demonstrate that the dynamic regulation of DNA methylation is a critical epigenetic mechanism of cancer initiation, maintenance, and progression. Proper control of DNA methylation is not only crucial for regulating gene transcription and tissue-specific cellular functions, but its broader consequences include maintaining the integrity of the genome and modulating the immune response. Here, we describe the aberrant DNA methylation changes in human cancers and how they contribute to the disease phenotypes. Aside from CpG island promoter DNA hypermethylation-based gene silencing, human cancers also display gene body DNA hypomethylation that is also associated with downregulated gene expression. In addition, the implementation of whole genome bisulfite sequencing (WGBS) has unveiled DNA hypomethylation of large blocks of the genome, known as partially methylated domains (PMDs), as well as cancer-specific DNA methylation aberrancies at enhancers and super-enhancers. Integrating WGBS and DNA methylation array data with mutation, copy number, and gene expression data has allowed for the identification of novel tumor suppressor genes and candidate driver genes of the disease state. Finally, we highlight potential clinical implications of these changes in the context of prognostic and diagnostic biomarkers, as well as therapeutic targets. Mounting evidence shows that DNA methylation data are effective and highly-sensitive disease classifiers, not only from analyses of the primary tumor but also from tumor-derived, cell free DNA (cfDNA) in blood of cancer patients. These findings highlight the power of DNA methylation aberrancies in providing efficacious biomarkers for clinical utility in improving patient diagnostics and their reversal using DNA methylation inhibitors in cancer treatment may be key in surveillance, treatment, and quality of life for cancer patients.

DNA methylation, its mediators and genome integrity.

Deoxyribonucleic Acid 5-Hydroxymethylation in Cell-Free Deoxyribonucleic Acid, a Novel Cancer Biomarker in the Era of Precision Medicine

The Molecular Basis Of Dna Demethylation

DNA Methylation: From Cancer Biology to Clinical Perspectives

Circulating Methylated DNA As Biomarkers for Cancer Detection

The interplay between DNA and histone methylation: molecular mechanisms and disease implications

Uncoordinated expression of DNA methylation-related enzymes in human cancer

Mutations in DNA Methyltransferases and Demethylases

DNA Methyltransferases and Their Roles in Tumorigenesis

Ten-eleven translocation proteins (TETs): tumor suppressors or tumor enhancers?

Genome-wide Distribution of DNA Methylation and DNA Demethylation and Related Chromatin Regulators in Cancer

The Role of DNA Methylation and DNA Methyltransferases in Cancer

Cytosine Modifications and Distinct Functions of TET1 on Tumorigenesis

DNA methylation: Precise modulation of chromatin structure and dynamics

Dna Methyltransferases and Methyl-Binding Proteins of Mammals

DNA Hypermethylation As a Chemotherapy Target.

Aberrant DNA Methylation and Genome Instability and Mutation in Cancer

Relationship Between DNA Methylation/demethylation and Cancer

DNA Methylation and Histone Deacetylation: Interplay and Combined Therapy in Cancer

Emerging role of different DNA methyltransferases in the pathogenesis of cancer

DNA Methylation Profiles in Cancer Diagnosis and Therapeutics